{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"Within Normal Limits"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"title":"Above ULN"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Data is presented as number of patients\n\n* Within the reference limits (see below)\n* Above ULN (Upper Limits of Normal)\n\nIn the Acromegaly group both males and females were included the age was between 42-70 years. The IGF normal range for the different genders and age are presented below.\n\nREFERENCE VALUES\n\nMales (NMOL/L) 8.34-27.44 (41-45 years) 7.7-26.36 (46-50 years) 7.3-26.34 (51-55 years) 6.64-25.44 (56-60 years) 6.17-25.02 (61-65 years) 5.96-25.48 (66-70 years)\n\nFemales (NMOL/L) 8.06-26.89 (41-45 years) 7.39-25.44 (46-50 years) 6.92-24.98 (51-55 years) 5.92-22.7 (56-60 years) 5.42-21.96 (61-65 years) 5.07-21.97 (66-70 years)","groups":[{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks\n\noctreotide FluidCrystal® injection depot","id":"OG000","title":"CAM2029 10 mg q2w (Acromegaly)"},{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly\n\noctreotide FluidCrystal® injection depot","id":"OG001","title":"CAM2029 20 mg q4w (Acromegaly)"}],"paramType":"NUMBER","populationDescription":"Pharmacokinetic population (5 acromegaly subjects total)","reportingStatus":"POSTED","timeFrame":"Day 84","title":"CAM2029 Effect on Insulin-like Growth Factor (IGF-1) (Acromegaly)","type":"SECONDARY","unitOfMeasure":"participants"}